BofA Securities Maintains Hims & Hers Health(HIMS.US) With Sell Rating, Maintains Target Price $22
Sell Rating Issued for Hims & Hers Health Amid FDA Concerns on Topical Finasteride
BofA Securities Maintains Hims & Hers Health(HIMS.US) With Sell Rating, Maintains Target Price $22
Sell Rating for Hims & Hers Health Due to Slowing Sales Growth and Regulatory Risks
Truist Financial Maintains Hims & Hers Health(HIMS.US) With Hold Rating, Announces Target Price $33
Hims & Hers Health Is Maintained at Hold by Truist Securities
Hims & Hers Health Analyst Ratings
Truist Cuts Price Target on Hims & Hers Health to $33 From $39, Keeps Hold Rating
Morgan Stanley Maintains Hims & Hers Health(HIMS.US) With Hold Rating, Maintains Target Price $60
Truist Financial Maintains Hims & Hers Health(HIMS.US) With Hold Rating
Truist Financial Sticks to Their Hold Rating for Hims & Hers Health (HIMS)
Sell Rating for Hims & Hers Health Amid Low Margin Concerns and Competitive Pricing
BofA Securities Maintains Hims & Hers Health(HIMS.US) With Sell Rating, Raises Target Price to $22
Hims & Hers Health Is Maintained at Underperform by B of A Securities
Hims & Hers Health Analyst Ratings
Sell Rating for Hims & Hers Health Amid Slowing Core Business Growth and Legal Challenges
Morgan Stanley Maintains Hims & Hers Health(HIMS.US) With Hold Rating, Maintains Target Price $60
BofA Securities Maintains Hims & Hers Health(HIMS.US) With Sell Rating, Maintains Target Price $21
Morgan Stanley Maintains Hims & Hers Health(HIMS.US) With Hold Rating, Maintains Target Price $60
BofA Securities Maintains Hims & Hers Health(HIMS.US) With Sell Rating, Maintains Target Price $21